CBMTG 2008 Presentations
Disclaimer
Reference to these materials will be useful but not comprehensive in developing appropriate standards of care. Their use does not confer any professional qualification or standard. Publication of these materials does not constitute an endorsement of CBMTG. CBMTG has not reviewed these materials to ensure consistency with acceptable practices. The views expressed in these materials represent the opinion of the authors. CBMTG expressly disclaims any liability arising from any inaccuracy or misstatement. Each facility and/or individual referring to these materials should analyze the information, practices and procedures outlined therein to determine their acceptability for use in the context of their own obligations and within their own facility's standards and procedures.
Speakers for the following presentations have given authorization to post their materials. The remaining presentations may be posted at a later date. Please revisit this page for updates.
Session 1
Long term side effects of stem cell transplantation
Gerard Socie
Session 2A - Basic Science
Mesenchymal Stromal Cells for therapy of hematological disorders
Jacques Galipeau
Session 2B - Clinical Issues
Sexuality in patients undergoing hematopoietic stem cell transplantation
Reanne Booker
Practical information on cord blood transplantation
Martin Champagne
Psychological and ethical issues in sibling donors
Marie-France Vachon
Session 2C - Pharmacological Aspects
Advanced strategies in GVHD treatment
Hanna Michalska
Pharmacokinetics of Mycophenolate Mofetil
Roxane Therrien
Antifungal prophylaxis in HSCT
Barbara Vadnais
Session 3 - Lymphoid Malignancies
Allogeneic transplantation in pediatric ALL: indications, results
Michael Pulsipher
Allogeneic transplantation for follicular lymphoma: indications, results
Koen van Besien
Session 4 - Hemoglobinaopathies: sickle cell
Myeloablative transplantation for sickle cell disease
Francoise Bernaudin
Session 5A - Reduced Intensity Conditioning Regimen
What is the upper age limit for nonmyeloablative allogeneic transplanation (related and unrelated)
Sergio Giralt
Chimerism kinetics and its significance
Frederic Baron
Session 5B - Stem Cell Laboratories - Problem Solving/Open Forum
Angeline Giftakis and Mike Halpenny
Session 7 - Oral Abstracts
Regulatory T Cells Spared by Photodynamic Therapy of Cells from Chronic Graft-versus-Host Disease Patients Inhibit Alloreactivity
Jean Philippe Bastien
A non-ATG-based conditioning regimen to allograft patients with severe aplastic anemia using peripheral blood stem cells
Omar Fahmy
Impact of intensity of conditioning therapy on the outcome of allografting in myelofibrosis with myeloid metaplasia: better survival with reduced intensity approach in patients > 50 years
Vikas Gupta
Allogeneic Stem Cell Transplant in First Complete Remission Improves Outcome in Acute Myeloid Leukemia with the FLT-3 Internal Tandem Duplication
Maryse Power
Regimen intensity in acute myelogenous leukaemia: Addition of 400cGy total body irradiation to a myeloablative fludarine/busulfan/thymoglobulin allogeneic transplant regimen reduces relapse without increasing transplant-related mortality
James Russell
Session 9 - GVHD
Gene expression profiling and GVHD
Claude Perreault
How I treat steroid refractory acute GVHD
Joachim Deeg
Session 10 - GVHD cont'd
How I treat steroid refractory chronic GVHD
Paul Carpenter
